Cypher Metaverse Inc. Announces Business Combination with Noninvasix

Cypher Metaverse Inc. has announced a letter of intent to merge with Noninvasix, Inc. The proposed transaction, set to be a Reverse Takeover under the Canadian Securities Exchange policies, will see Noninvasix become a wholly-owned subsidiary of Cypher. The shareholders of Noninvasix will receive common shares of the new merged entity.

Concurrent with the merger, Noninvasix plans an equity financing of $3 million USD. The funds will be allocated for working capital and corporate purposes. Cypher also considers providing Noninvasix with a bridge loan, forgivable upon the deal's completion. Trading of Cypher's shares remains halted pending regulatory approval.

The merger aims to leverage Noninvasix's medical technology innovations, expected to impact critical care diagnostics significantly. Further details, including financials and management plans, will be released upon finalizing a definitive agreement.